Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by[…]
Status
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Primary Outcome Measures Number of patients with adverse events and serious adverse events [ Time Frame: 3 years ] Safety and tolerability of IAG933 Incidence of dose limiting toxicities during the first treatment cycle (dose escalation only) [ Time Frame: 1 year ] Safety, tolerability and the maximum tolerated dose or recommended dose of IAG933 Number of patients[…]
Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will[…]
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (SCITH-MESO)
Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).
Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues
The purpose of the Dielectrics Properties of Thoracic Malignancies Study (DPTMS) is to provide a wealth of knowledge for investigators involved in establishing a new and effective treatment for a variety of solid tumors using tumor treatment fields. It is intended to provide biospecimen (tumor/healthy) together with demographic data (age, sex, race, occupational history, and other epidemiologic information), and clinical data (stage, treatment, survival information, and annotated CT’s). Our specific aims are to test the following hypotheses: 1) Electric properties of thoracic tumors differ from electric properties of surrounding healthy tissue 2) Different tumor types will have different electric properties 3) Electric properties of individual tumors are heterogeneous 4) Electric properties of tumors are related to the structure and composition of the underlying tissue 5) Use of standard medical imaging data (CT) will permit mapping of electric properties.
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Primary Outcome Measures Prevalence of germline BAP1 variants in the unselected general population of cancer patients [ Time Frame: 5 years ] Clinical phenotypes (this includes premalignant lesions, tumor type and age of onset) in at risk blood-line family members of the patients [ Time Frame: 5 years ] Secondary Outcome Measures Environmental risk factors modifying cancer risk[…]
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy (MESOIMMUNE)
Primary Outcome Measures Disease control [ Time Frame: 12 weeks ] Disease control rate at 12 weeks Secondary Outcome Measures Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ] Overall survival from treatment with anti-PD1/PDL1 immunotherapy Duration of treatment [ Time Frame: 12 weeks ] Duration of treatment with PD1/PDL1 immunotherapy Survival [ Time Frame: 12 weeks ] Overall survival from the start of the[…]
Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
Intravenous Magnesium in Patients Receiving Cisplatin
Primary Outcome Measures Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ] Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time[…]
